What is Parallel Bio?
Parallel Bio is pioneering a novel approach to drug discovery by integrating advanced organoid technology with artificial intelligence. The company has developed a unique platform capable of creating highly accurate models of human biology, including the complex human immune system across diverse populations. This 'Clinical Trial in a Dish' technology allows pharmaceutical partners, including three Fortune 500 companies, to predict drug efficacy and safety with unprecedented speed and accuracy, moving beyond the limitations of traditional animal models. Founded in 2021 by two scientists renowned for developing the world's first scalable human immune organoid, Parallel Bio is based in Cambridge, Mass., and is poised to accelerate the development of life-saving immunotherapies.
How much funding has Parallel Bio raised?
Parallel Bio has raised a total of $25.3M across 2 funding rounds:
Angel/Seed
$4.3M
Series A
$21M
Angel/Seed (2022): $4.3M with participation from Refactor Capital, Breakout Ventures, and Y Combinator
Series A (2025): $21M led by Atypical Ventures, Metaplanet, Amplo, AIX Ventures, and Undeterred Capital
Key Investors in Parallel Bio
Atypical Ventures
Atypical Ventures is a venture capital firm operating within the Venture Capital & Private Equity sector, likely focusing on companies with significant growth potential.
Metaplanet
Metaplanet is an early-stage investment firm that backs mission-driven founders working on disruptive deep technologies, with a focus on positively impacting humanity's survival and societal progress.
Amplo
Amplo is a global venture capital firm that invests in innovative startups across healthcare, financial services, and technology, aiming to support ambitious companies that can make a significant difference.
What's next for Parallel Bio?
With the recent infusion of major strategic capital, Parallel Bio is well-positioned to further scale its innovative drug discovery platform. The company's focus on replicating human biology, particularly the immune system, addresses a critical bottleneck in pharmaceutical R&D. This substantial backing will likely fuel advancements in platform capabilities, expansion of its pharmaceutical partnerships, and potentially the acceleration of its own therapeutic pipeline. The company's trajectory suggests a move towards broader clinical validation and market penetration, solidifying its role as a key player in the future of precision medicine and drug development.
See full Parallel Bio company page
